Cingulate Inc.

CING ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Operating Activities
Net Income $-22.4M $-16.6M $-23.5M $-17.7M $-20.7M $-7.2M
Depreciation & Amortization — — — — — —
Depreciation $540.9K $653.1K $582.9K $394.0K $708.3K $666.0K
Amortization — — — — — —
Stock-Based Compensation $1.5M $995.5K $812.7K $800.8K $43.8K —
Net Cash from Operating Activities $-17.2M $-18.5M $-15.0M $-15.9M $-10.4M $-6.8M
Investing Activities
Capital Expenditures $162.1K $211.8K $224.1K $153.4K $814.7K $402.1K
Business Acquisitions — — — — — —
Net Cash from Investing Activities $-162.1K $-211.8K $-224.1K $-152.7K $-814.7K $-384.2K
Financing Activities
Dividends Paid — — — — — —
Stock Repurchases — — — — — —
Net Cash from Financing Activities $16.1M $30.8M $10.0M $4.9M $26.5M $8.0M
Net Change in Cash $-1.3M $12.2M $-5.3M $-11.1M $15.3M —
Free Cash Flow $-17.4M $-18.7M $-15.3M $-16.0M $-11.2M $-7.2M